Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Palvella Therapeutics, Inc (PVLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PVLA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.33
1 Year Target Price $37.33
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.09% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.38M USD | Price to earnings Ratio 9.92 | 1Y Target Price 37.33 |
Price to earnings Ratio 9.92 | 1Y Target Price 37.33 | ||
Volume (30-day avg) 9 | Beta - | 52 Weeks Range 11.17 - 47.97 | Updated Date 05/31/2025 |
52 Weeks Range 11.17 - 47.97 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 9.92 | Forward PE - | Enterprise Value 213128551 | Price to Sales(TTM) - |
Enterprise Value 213128551 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 11221300 | Shares Floating 3351754 |
Shares Outstanding 11221300 | Shares Floating 3351754 | ||
Percent Insiders 17.5 | Percent Institutions 36.51 |
Upturn AI SWOT
Palvella Therapeutics, Inc
Company Overview
History and Background
Palvella Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare, genetically-defined dermatologic diseases. Founded to address unmet needs in this area, the company has advanced clinical programs targeting conditions with limited or no approved treatment options.
Core Business Areas
- Rare Dermatologic Diseases: Palvella focuses on developing and commercializing therapies for rare, genetically-defined dermatologic diseases, including pachyonychia congenita (PC).
Leadership and Structure
Details on the leadership team and organizational structure were not found in public sources.
Top Products and Market Share
Key Offerings
- QTORIN (recieved FDA approval in March 2024): QTORIN is designed to treat pachyonychia congenita (PC). Data on specific market share or revenue is currently unavailable due to it being newly FDA approved. Key competitors in rare dermatology drug development include companies focusing on similar genetic conditions, such as BridgeBio Pharma and others developing treatments for related skin disorders.
Market Dynamics
Industry Overview
The rare disease therapeutics market is characterized by high unmet needs, regulatory incentives (e.g., orphan drug designation), and potentially high pricing power. Development is challenging due to small patient populations and the need for specialized expertise.
Positioning
Palvella positions itself as a leader in rare, genetically-defined dermatologic diseases, particularly PC. Its competitive advantage lies in its focus and specialized expertise in this niche area.
Total Addressable Market (TAM)
The TAM for PC therapeutics is relatively small due to the rarity of the condition. Palvella's QTORIN seeks to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Specialized expertise in rare dermatologic diseases
- QTORIN FDA approval
- Focus on unmet medical needs
Weaknesses
- Reliance on a limited number of products
- Small patient population, limiting market size
- Potential challenges in drug manufacturing and distribution
Opportunities
- Expansion into other rare dermatologic diseases
- Partnerships with larger pharmaceutical companies
- Further clinical development of existing pipeline candidates
Threats
- Competition from other companies developing similar therapies
- Regulatory hurdles and potential delays in approval
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
Competitive Landscape
Due to the limited information available and it being a private company, information on their competitive landscape cannot be adequately assessed.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not available from public sources.
Future Projections: Future growth projections are currently not available due to lack of data and recency of the FDA approval.
Recent Initiatives: Recent initiatives include FDA approval of QTORIN for pachyonychia congenita (PC).
Summary
Palvella Therapeutics is a biopharmaceutical company focused on rare dermatologic diseases and has achieved a significant milestone with the FDA approval of QTORIN. Its strength lies in its specialized focus, however, it faces challenges associated with a limited market size and potential competition. Further growth will depend on expanding its pipeline and strategic partnerships. The company's overall financial picture remains uncertain until more detailed financial data become available after the merger with Royalty Management Holding Corporation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Palvella Therapeutics Website
- FDA Press Releases
- Company information sources
Disclaimers:
The information provided is based on limited publicly available data. Financial data and market share estimates are based on general industry knowledge and may not be precise. This analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palvella Therapeutics, Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2024-12-16 | Founder, President, CEO & Director Mr. Wesley H. Kaupinen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://palvellatx.com |
Full time employees 14 | Website https://palvellatx.com | ||
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.